- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 5/16 - Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
Patent holdings for IPC class A61P 5/16
Total number of patents in this class: 114
10-year publication summary
|
0
|
2
|
5
|
8
|
11
|
15
|
6
|
7
|
17
|
7
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Kissei Pharmaceutical Co., Ltd. | 178 |
6 |
| Philip Morris Products S.A. | 8291 |
4 |
| Daiichi Sankyo Company, Limited | 1890 |
4 |
| Hinova Pharmaceuticals Inc. | 104 |
4 |
| F. Hoffmann-La Roche AG | 7798 |
3 |
| Vertex Pharmaceuticals Incorporated | 1577 |
3 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 877 |
3 |
| Sunshine Lake Pharma Co., Ltd. | 631 |
3 |
| KPC Pharmaceuticals, Inc. | 31 |
3 |
| Changchun Genescience Pharmaceutical Co., Ltd. | 149 |
3 |
| Inventisbio Co., Ltd. | 84 |
3 |
| Shanghai Kunheng Pharma-tech Co., Ltd | 9 |
3 |
| Jiangsu Hengrui Medicine Co., Ltd. | 686 |
2 |
| Osaka University | 3257 |
2 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 722 |
2 |
| Academy of Military Medical Sciences | 143 |
2 |
| Regcell Co., Ltd. | 21 |
2 |
| Viridian Therapeutics, Inc. | 62 |
2 |
| Takeda Pharmaceutical Company Limited | 2700 |
1 |
| University of Florida Research Foundation, Inc. | 4207 |
1 |
| Other owners | 58 |